Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017

Date: December 29, 2017
Pages: 164
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: R61ADF79FA1EN
Leaflet:

Download PDF Leaflet

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.

Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 9, 3, 1, 25 and 9 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 10 molecules, respectively.

Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Global Markets Direct Report Coverage
Retinitis Pigmentosa (Retinitis) - Overview
Retinitis Pigmentosa (Retinitis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development
2-BBB Medicines BV
Acucela Inc
Allergan Plc
Amarantus Bioscience Holdings Inc
Amgen Inc
Applied Genetic Technologies Corp
Astellas Pharma Inc
Caladrius Biosciences Inc
Dompe Farmaceutici SpA
Eyevensys SAS
GenSight Biologics SA
Grupo Ferrer Internacional SA
ID Pharma Co Ltd
InFlectis BioScience
Ionis Pharmaceuticals Inc
M's Science Corp
MimeTech Srl
Mimetogen Pharmaceuticals Inc
Nanovector srl
Novartis AG
Novelion Therapeutics Inc
ProQR Therapeutics NV
Recursion Pharmaceuticals Inc
ReNeuron Group Plc
SanBio Inc
Sanofi
Spark Therapeutics Inc
Sun Pharma Advanced Research Company Ltd
Retinitis Pigmentosa (Retinitis) - Drug Profiles
A-004 - Drug Profile
AGTC-501 - Drug Profile
AMRS-001 - Drug Profile
Antibodies to Antagonize IL-6 for Retinitis - Drug Profile
Antisense Oligonucleotides to Activate Usherin for Retinitis Pigmentosa - Drug Profile
AP-1 - Drug Profile
cenegermin - Drug Profile
CPK-850 - Drug Profile
cutamesine - Drug Profile
EYS-611 - Drug Profile
FAB-111 - Drug Profile
Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa - Drug Profile
Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile
Gene Therapy for Ocular Diseases - Drug Profile
Gene Therapy for Retinitis Pigmentosa - Drug Profile
Gene Therapy for Retinitis Pigmentosa - Drug Profile
Gene Therapy to Activate Glutamate Cysteine Ligase and Glutathione Synthase for Retinitis Pigmentosa - Drug Profile
Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile
Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile
Gene Therapy to Activate mVChR1 for Retinits Pigmentosa - Drug Profile
Gene Therapy to Activate RdCVF for Retinitis Pigmentosa - Drug Profile
Gene therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile
Gene Therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile
GS-030 - Drug Profile
HORAPDE-6B - Drug Profile
HORARLBP-1 - Drug Profile
HORARPE-65 - Drug Profile
IFB-088 - Drug Profile
IONISRHO-2.5Rx - Drug Profile
KIRA-6 - Drug Profile
KUS-121 - Drug Profile
KUS-187 - Drug Profile
LPDF-003 - Drug Profile
MT-8 - Drug Profile
myriocin - Drug Profile
N-acetyl cysteine amide - Drug Profile
NPI-001 - Drug Profile
NT-501 - Drug Profile
OCU-100 - Drug Profile
QRX-411 - Drug Profile
QRX-421 - Drug Profile
ReN-003 - Drug Profile
RST-001 - Drug Profile
SAR-421869 - Drug Profile
SB-623 - Drug Profile
Small Molecule for Retinitis Pigmentosa - Drug Profile
Small Molecules 1 for Retinitis Pigmentosa - Drug Profile
Small Molecules 2 for Retinitis Pigmentosa - Drug Profile
Small Molecules 3 for Retinitis Pigmentosa - Drug Profile
Small Molecules 4 for Retinitis Pigmentosa - Drug Profile
Small Molecules for Retinitis Pigmentosa - Drug Profile
Small Molecules to Block Cyclic Nucleotide Gated Channel for Retinitis Pigmentosa - Drug Profile
Small Molecules to Inhibit Ire1-Alpha for Retinitis Pigmentosa, Type 2 Diabetes and Amyotrophic Lateral Sclerosis - Drug Profile
STC-1 - Drug Profile
Stem Cell Therapy for AMD and Retinitis Pigmentosa - Drug Profile
Stem Cell Therapy for Ophthalmic Disorders - Drug Profile
Stem Cell Therapy for Retinitis Pigmentosa - Drug Profile
Stem Cell Therapy for Retinitis Pigmentosa and Age Related Macular Degeneration - Drug Profile
Stem Cell Therapy to Activate RPGR for Retinitis Pigmentosa - Drug Profile
voretigene neparvovec - Drug Profile
zuretinol acetate - Drug Profile
Retinitis Pigmentosa (Retinitis) - Dormant Projects
Retinitis Pigmentosa (Retinitis) - Discontinued Products
Retinitis Pigmentosa (Retinitis) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by 2-BBB Medicines BV, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Allergan Plc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Amgen Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corp, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Astellas Pharma Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Caladrius Biosciences Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici SpA, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Eyevensys SAS, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by GenSight Biologics SA, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Grupo Ferrer Internacional SA, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by ID Pharma Co Ltd, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by InFlectis BioScience, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by M's Science Corp, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by MimeTech Srl, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Mimetogen Pharmaceuticals Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Nanovector srl, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Novartis AG, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Novelion Therapeutics Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by ProQR Therapeutics NV, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Recursion Pharmaceuticals Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by ReNeuron Group Plc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by SanBio Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Sanofi, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Spark Therapeutics Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Retinitis Pigmentosa (Retinitis) - Dormant Projects, H2 2017
Retinitis Pigmentosa (Retinitis) - Dormant Projects, H2 2017 (Contd.1), H2 2017
Retinitis Pigmentosa (Retinitis) - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

2-BBB Medicines BV
Acucela Inc
Allergan Plc
Amarantus Bioscience Holdings Inc
Amgen Inc
Applied Genetic Technologies Corp
Astellas Pharma Inc
Caladrius Biosciences Inc
Dompe Farmaceutici SpA
Eyevensys SAS
GenSight Biologics SA
Grupo Ferrer Internacional SA
ID Pharma Co Ltd
InFlectis BioScience
Ionis Pharmaceuticals Inc
M's Science Corp
MimeTech Srl
Mimetogen Pharmaceuticals Inc
Nanovector srl
Novartis AG
Novelion Therapeutics Inc
ProQR Therapeutics NV
Recursion Pharmaceuticals Inc
ReNeuron Group Plc
SanBio Inc
Sanofi
Spark Therapeutics Inc
Sun Pharma Advanced Research Company Ltd
Skip to top


Retinal Vein Occlusion - Pipeline Review, H1 2017 US$ 2,000.00 Jun, 2017 · 74 pages

Ask Your Question

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: